Company news
Palvella Therapeutics, Inc. (NASDAQ:PVLA) news
Every Palvella Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 3, 2026
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 2, 2026
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PAC...
May 21, 2026
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at...
May 15, 2026
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Ligand to Participate in May Investor Conferences
May 5, 2026
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Sign...
May 4, 2026
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for ...
April 20, 2026
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
April 13, 2026
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 7, 2026
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 31, 2026
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeu...
March 30, 2026
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American ...
March 27, 2026
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
March 24, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice...
March 23, 2026
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
March 16, 2026
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Lead...
March 10, 2026
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Pu...
March 2, 2026
Palvella Therapeutics Announces Pricing of Upsized Public Offering
February 25, 2026
Palvella Therapeutics Announces Proposed Public Offering
February 24, 2026
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORI...
February 24, 2026
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhy...
February 23, 2026
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhy...
February 23, 2026
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-...
February 2, 2026
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multip...
January 9, 2026
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice ...
January 7, 2026
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment o...
December 16, 2025
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORI...
December 15, 2025
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORI...
December 15, 2025
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 11, 2025
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
November 6, 2025
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actini...
November 5, 2025
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
November 4, 2025
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Tri...
October 13, 2025
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronica...
September 24, 2025
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis...
September 17, 2025
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
September 15, 2025
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne,...
September 3, 2025
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
August 28, 2025
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
August 7, 2025
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
June 30, 2025